Brief: Oramed Reports Positive Top-Line Results From Phase 2 NASH Trial

Oramed Pharmaceuticals

13/09/2022 14:49

Sept 13 (Reuters) - Oramed Pharmaceuticals Inc  ORMP.O :
    * ORAMED REPORTS POSITIVE TOP-LINE RESULTS FROM PHASE 2 NASH
TRIAL
WITH ITS ORMD-0801, ORAL INSULIN CANDIDATE
    * ORAMED PHARMACEUTICALS INC - PRIMARY ENDPOINT MET:
ORMD-0801 WAS
SAFE AND WELL TOLERATED
    * ORAMED PHARMACEUTICALS INC - SECONDARY ENDPOINT MET:
ORMD-0801
SHOWED CLINICALLY MEANINGFUL REDUCTION OF LIVER FAT FROM
BASELINE AT 12 WEEKS
    * ORAMED PHARMACEUTICALS INC - AWAIT TOP-LINE DATA FROM
PHASE 3
TRIAL OF ORAL INSULIN FOR T2D, WHICH WE EXPECT IN JANUARY 2023

Source text for Eikon:  ID:nPnb7SPZLa 
Further company coverage:  ORMP.O 

 ((Reuters.Briefs@thomsonreuters.com;))